公开(公告)号：US20180185319A1

公开(公告)日：2018-07-05

申请号：US15910745

申请日：2018-03-02

申请人： Biogen MA Inc.

发明人： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC分类号： A61K31/225 ,  A61K45/06 ,  A61K31/60 ,  A61K9/28 ,  A61K9/20 ,  A61K9/48 ,  A61K9/16 ,  A61K31/616

CPC分类号： A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

摘要： Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US10004729B2

公开(公告)日：2018-06-26

申请号：US15606112

申请日：2017-05-26

申请人： COLLEGIUM PHARMACEUTICAL, INC.

发明人： Roman V. Rariy ,  Alison Fleming ,  Jane C. Hirsh ,  Said Saim ,  Ravi K. Varanasi

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K31/44 ,  A61K31/485 ,  A61K9/48 ,  B29C70/60 ,  A61K9/50 ,  A61K47/12 ,  A61K47/44 ,  A61K9/20

CPC分类号： A61K31/485 ,  A61K9/14 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1664 ,  A61K9/1694 ,  A61K9/4808 ,  A61K9/5042 ,  A61K47/12 ,  A61K47/44 ,  B29C70/60

摘要： Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.

公开(公告)号：US20180161281A1

公开(公告)日：2018-06-14

申请号：US15832432

申请日：2017-12-05

申请人： Lupin Atlantis Holdings SA

发明人： Velayutham Kanniyappan ,  James Garegnani

IPC分类号： A61K9/50 ,  A61K9/48 ,  A61K31/137

CPC分类号： A61K9/5073 ,  A61K9/1676 ,  A61K9/4808 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5078 ,  A61K31/137

摘要： A long-acting pharmaceutical composition comprising at least one amphetamine salt is provided. The composition comprises an immediate release component, a delayed release component, and a sustained release component comprising one or more amphetamine salts. The sustained release component comprises a sustained release layer and a delayed release layer, such that the delayed release layer is coated onto the sustained release layer. The time (Tmax) to achieve Cmax after administration of said composition is between 7-10 hours.

公开(公告)号：US20180140553A1

公开(公告)日：2018-05-24

申请号：US15718000

申请日：2017-09-28

申请人： APeT Holding B.V.

发明人： Hendrik Jan Cornelis Meijerink ,  Lekhram Changoer ,  Willem Blom ,  Marinella Regina Visser ,  Henderik Willem Frijlink ,  Anko Cornelus Eissens

IPC分类号： A61K9/16 ,  G01N33/68 ,  A61K31/455 ,  A61K31/198 ,  A61K9/48 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K9/1652 ,  A61K9/0065 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1676 ,  A61K9/2054 ,  A61K9/4808 ,  A61K9/4891 ,  A61K31/198 ,  A61K31/455 ,  G01N33/6893 ,  Y10T436/143333

摘要： The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

公开(公告)号：US09962344B2

公开(公告)日：2018-05-08

申请号：US15289713

申请日：2016-10-10

申请人： ELCELYX THERAPEUTICS, INC.

发明人： Alain D. Baron ,  Nigel R. A. Beeley ,  Mark S. Fineman

IPC分类号： A61K31/155 ,  A61K9/20 ,  A61K9/24 ,  A61K9/28 ,  A61K9/48 ,  A61K9/00 ,  A61K31/19 ,  A61K31/198 ,  A61K31/7016 ,  A61K31/704 ,  A61K45/06

CPC分类号： A61K31/155 ,  A61K9/0053 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/19 ,  A61K31/198 ,  A61K31/7016 ,  A61K31/704 ,  A61K45/06

摘要： Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

公开(公告)号：US09956538B2

公开(公告)日：2018-05-01

申请号：US14764832

申请日：2014-02-13

申请人： Agency for Science, Technology and Research

发明人： Jia Min Chin ,  Siok Wei Tay ,  Xiaobai Wang ,  Jianwei Xu ,  Andy Tzi Sum Hor

IPC分类号： A61K9/48 ,  B01J19/12 ,  A61K41/00 ,  C05G3/00 ,  G21K5/02 ,  A61K9/50 ,  B82Y5/00 ,  B82Y30/00

CPC分类号： B01J19/12 ,  A61K9/4808 ,  A61K9/501 ,  A61K9/5015 ,  A61K41/0028 ,  B01J2219/089 ,  B01J2219/12 ,  B82Y5/00 ,  B82Y30/00 ,  C05G3/0005 ,  C05G3/0017 ,  C05G3/0041 ,  C05G3/0076 ,  G21K5/02

摘要： The invention relates to macro- and micro-liquid marbles (i.e. droplets of liquid with a particulate-based shell), and in particular, to photo-responsive macro- and micro-liquid marbles encapsulating a substance therein. Methods for forming the macro- and micro-liquid marbles, and use of the macro- and micro-liquid marbles, in controlled release applications are also disclosed.

公开(公告)号：US09956292B2

公开(公告)日：2018-05-01

申请号：US14826115

申请日：2015-08-13

申请人： Cedars-Sinai Medical Center ,  Synthetic Biologics, Inc.

发明人： Mark Pimentel ,  Ruchi Mathur ,  Steve Kanzer ,  Vince Wacher

IPC分类号： A61K47/38 ,  A61K31/351 ,  A61K47/12 ,  A61K47/18 ,  A61K9/28 ,  A61K9/48 ,  A61K31/00

CPC分类号： A61K47/38 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2886 ,  A61K9/4808 ,  A61K31/00 ,  A61K31/351 ,  A61K47/12 ,  A61K47/183

摘要： The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

公开(公告)号：US20180099053A1

公开(公告)日：2018-04-12

申请号：US15496751

申请日：2017-04-25

申请人： Lipocine Inc.

发明人： David Fikstad ,  Srinivasan Venkateshwaran ,  Chandrashekar Giliyar ,  Mahesh Patel

IPC分类号： A61K47/44 ,  A61K31/225 ,  A61K31/35 ,  A61K9/16 ,  A61K9/48 ,  A61K47/14 ,  A61K31/403 ,  A61K9/20 ,  A61K47/10 ,  A61K31/355 ,  A61K31/17 ,  A61K31/366 ,  A61K31/34 ,  A61K47/22 ,  A61K31/568 ,  A61K31/28 ,  A61K31/401 ,  A61K47/40 ,  A61K31/265 ,  A61K31/66 ,  A61K47/12 ,  A61K31/404 ,  A61K31/4709 ,  A61K47/34 ,  A61K9/00 ,  A61K31/724 ,  A61K47/26

CPC分类号： A61K47/44 ,  A61K9/0004 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/4808 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/17 ,  A61K31/225 ,  A61K31/265 ,  A61K31/28 ,  A61K31/34 ,  A61K31/35 ,  A61K31/355 ,  A61K31/366 ,  A61K31/401 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4709 ,  A61K31/568 ,  A61K31/66 ,  A61K31/724 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/40

摘要： Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

公开(公告)号：US20180093084A1

公开(公告)日：2018-04-05

申请号：US15832464

申请日：2017-12-05

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61M37/00 ,  A61K38/27 ,  A61M5/00 ,  A61M25/10 ,  A61M29/02 ,  C07K16/28 ,  C07K16/18 ,  A61K9/48 ,  A61M31/00

CPC分类号： A61M37/0015 ,  A61K9/4808 ,  A61K38/27 ,  A61M5/00 ,  A61M25/10 ,  A61M29/02 ,  A61M31/002 ,  A61M2037/0023 ,  A61M2037/0061 ,  A61M2210/1042 ,  C07K16/18 ,  C07K16/2848

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20180085315A1

公开(公告)日：2018-03-29

申请号：US15724767

申请日：2017-10-04

申请人： ALKERMES PHARMA IRELAND LIMITED

发明人： Gary Liversidge ,  David Manser ,  Hardik Shah ,  Stephen B. Ruddy ,  Gurvinder S. Rekhi

IPC分类号： A61K9/16 ,  A61K31/192 ,  A61K9/48 ,  A61K31/00 ,  A61K9/51 ,  A61K31/4439 ,  A61K31/381 ,  A61K31/216

CPC分类号： A61K9/1652 ,  A61K9/1635 ,  A61K9/4808 ,  A61K9/5138 ,  A61K9/5161 ,  A61K31/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/381 ,  A61K31/4439

摘要： Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.